Overview
- An FDA advisory panel narrowly recommended that six experimental peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — be added to the Section 503A bulks list for state-licensed compounding pharmacies.
- Career FDA scientists told the panel the peptides lack consistent chemical definitions, reference standards, and robust human safety or effectiveness data.
- At least six newly added advisory committee members had ties to peptide clinics or businesses, prompting federal concern about conflicts of interest in the vote.
- Reporting shows millions of Americans obtain unapproved peptides through a gray market, often from overseas suppliers with uncertain purity and manufacturing controls, and analysts project large telehealth sales if access is broadened.
- Experts and commentators urge that any move to permit compounding be paired with a federally coordinated research and safety-surveillance program, such as an NIH-led effort, because formal rulemaking and evidence collection would be needed before routine medical use.